This is a phase II study of the combination of panitumumab with irinotecan in malignant
glioma patients. The primary objective of the study is to determine the activity of the
combination of panitumumab with irinotecan as measured by 6-month progression-free survival.
Secondary objectives include the following- to determine the safety of panitumumab in
combination with irinotecan in patients with malignant glioma; to determine the effect of
panitumumab in combination with irinotecan on corticosteroid dose for each patient; to
explore any relationship between epidermal growth factor receptor (EGF-R) mutational analysis
and efficacy or toxicity; and, to determine the response rate and overall survival of
recurrent glioblastoma (GBM) patients treated with panitumumab in combination with
irinotecan.
The patients will have histologically documented grade 4 malignant gliomas (glioblastoma
multiforme or gliosarcoma) that have failed at least one prior chemotherapy regimen and all
patients will have received radiation therapy. This study will investigate second or greater
line of therapy for recurrent grade 4 malignant glioma. The patient population will include
32 patients.
The patients will undergo a baseline magnetic resonance imaging (MRI) as well as a MRI after
every six-week cycle to determine response and progression. After 16 patients with recurrent
GBM are treated, an interim analysis will be conducted. The most common side effects
associated with panitumumab have been dermatological (skin) problems such as erythema
(redness of the skin), acneiform rash (skin eruptions of the face), skin exfoliation,
pruritus (itching), skin fissures (skin tears), xerosis (dryness of the eye, skin, or mouth),
and rash. The most common side effects associated with irinotecan have been decreased blood
counts of platelets (increased risk of bleeding), white blood cells (increased risk of
infection), red blood cells (anemia); diarrhea, constipation, nausea, vomiting, tiredness,
fever, mouth sores, dehydration (excessive loss of body fluids), rash, itching, changes in
skin color, swelling, numbness, tingling, dizziness, confusion, low blood pressure, sweating,
hot flashes, hair loss, inflammation of the liver, flu-like symptoms, decreased urine output,
shortness of breath, and pneumonia (inflammatory disease of the lungs).